Clinical trial responsibility matrix development should begin before sponsor, CRO, laboratory, data-management and technology teams start exchanging deliverables. A useful matrix identifies the person who performs each activity, the person authorized to decide, the required handoff evidence, and what happens when a decision stalls. Completing this work at kickoff helps prevent operational gaps that a simple organizational chart will not expose.
This practical guide is for a lean biotech sponsor, Clinical Operations leader or project manager coordinating a Phase I or Phase II program with several providers. Its distinctive tool is a decision-to-evidence map: a responsibility row is not approved until it includes an owner, an approval path, a controlled output, and an escalation trigger.
Begin with a boundary: operational roles are not regulatory transfers
A RACI can describe the sponsor’s day-to-day operating model, but a RACI cell is not automatically a legal transfer of regulatory obligations. For U.S. IND drug trials, 21 CFR 312.52 requires any transferred sponsor obligations to a CRO to be described in writing. ICH E6(R3) Good Clinical Practice guidance emphasizes appropriately documented service-provider responsibilities and sponsor oversight. Check the actual contract, scope of work, transfer record, regulations and study governance together; a colored spreadsheet alone cannot reconcile them.
The matrix should also avoid vague labels such as "CRO" or "sponsor" when two people could both claim the same task. Use a named function, accountable decision role and designated backup, with an organizational owner that can be updated when staff change.
Step 1: Establish the process inventory, not just a list of departments
Start with the trial’s protocol, schedule of activities, development milestone plan, vendor scope documents and quality agreements. Break work into meaningful decisions and deliverables. A useful granularity is "approve randomization specifications" rather than "data management"; and "respond to a critical central lab result" rather than "central laboratory."
Map the following interfaces before kickoff: protocol and amendments; site startup and activation; safety surveillance and expedited reporting; vendor data transfers; investigational product and supplies; electronic data capture and changes; protocol deviations and CAPA; statistical outputs; TMF filing; trial financial approvals; and database lock. Some execution activities may be performed by specialist partners; name that delivery model accurately.
Step 2: Assign performance, decision and consultation separately
For each row, record the team that performs the work, a single operational decision authority when possible, the experts whose input is required, and the parties to notify. An operational "Accountable" role does not remove a sponsor’s statutory or GCP responsibilities. If one task has two legally necessary approvals, make two explicit approval steps rather than obscuring them with two ambiguous A’s.
Use the clinical trial responsibility matrix to distinguish a document’s author, scientific reviewer, quality reviewer, final approver and publisher where those functions matter. Confirm that approvals have the correct system permissions and a substitute for an absent decision maker.
| Trial decision or output | Responsible performer | Operational decision owner | Required evidence | Escalation signal |
|---|---|---|---|---|
| Protocol amendment impact | Clinical operations + functional leads | Sponsor clinical development lead | Approved impact assessment and revised plan | No owner for downstream changes |
| EDC edit-check release | Data management vendor | Sponsor data-management owner | Signed UAT and controlled release record | Protocol changes but UAT scope unchanged |
| Safety reconciliation | Safety vendor + clinical data | Sponsor safety/medical representative | Reconciliation report and issue closure | Repeated discrepancies remain open |
| Site activation | Site startup lead or partner | Delegated activation decision authority | Required approvals, contract and essential document checks | Site date promised before prerequisites |
| Database lock | Data management + statistics | Sponsor-authorized lock approver | Lock checklist, data transfer and deviation assessment | Unresolved critical queries or outputs |
Illustrative planning rows only; replace named parties, evidence and responsibilities with the study-specific agreements and applicable requirements.
Step 3: Add the evidence and handoff fields
A matrix that identifies owners but omits proof still leaves the project exposed. Append fields for: applicable document or clause; deliverable definition; evidence repository and file identifier; version; due milestone; predecessor; successor; quality check; approval record; delegated backup; and escalation route. The table can be kept compact with linked references to controlled plans.
For each vendor interface, ask: "What exactly proves this task is finished, who accepts it, and who needs the accepted version next?" In a multi-provider trial, the answer often crosses company boundaries. If only one team knows the answer, the handoff is not yet controlled.
Step 4: Run a decision simulation before kickoff
Test at least four realistic events in the meeting rather than merely circulating the sheet for signature.
- A central laboratory data transfer fails shortly before an interim review. Who detects it, who authorizes a revised cut, and who signs off the data integrity assessment?
- A protocol amendment adds an endpoint that changes EDC forms, training and the analysis plan. Who owns the impact register and the cross-vendor release sequence?
- A safety case needs follow-up at a site whose coordinator is unavailable. Who contacts the site, who provides medical judgment, and where is that exchange documented?
- An unexpected vendor change affects the site’s schedule. Who decides the revised milestone and whether the change requires budget and quality approval?
Capture each ambiguous answer as a tracked issue with a decision owner and deadline. Do not call the matrix approved while material decision gaps remain.
Step 5: Approve the matrix and connect it to governance
Use a controlled version, effective date and change history. The sponsor should determine whether the matrix is an appendix to the project management plan, a governed responsibility agreement, or a linked operational artifact. Define where it is stored and whether a protocol amendment, vendor replacement, contract change, new system or serious quality incident triggers review.
A sensible kickoff gate has four tests: functions named; approval rights confirmed; evidence and handoffs tested; and contractual/regulatory alignment checked. Reconcile any contradictory documents and record the decision. Approval should include the people who can actually commit the resources required.
Common failure modes and fixes
One function is accountable for everything. This creates a false single point of control. Split large activities into decisions with identifiable approvers; retain sponsor oversight separately.
The matrix stops at the CRO boundary. A specialty laboratory or technology vendor receives an unclear instruction. Add provider-to-provider handoffs and a sponsor owner for interface governance.
A protocol change updates the schedule but not the roles. Incorporate role-matrix review into change control so new evidence paths, training and approvals are assessed together.
An employee name is treated as permanent ownership. Tie responsibility first to the controlled role and then to a named individual and backup, updating both when personnel change.
A signed RACI is treated as a transfer of obligations. Confirm whether a written contractual transfer is required and exists for the actual obligation; maintain the distinction between a coordination chart and regulatory responsibilities.
A concise kickoff readiness check
Before releasing the operating model to vendors, verify: each high-risk task has a performer, decision owner and backup; every key deliverable has acceptance criteria and an evidence location; every handoff has a recipient and timing trigger; contract and transfer records agree with the matrix; escalation paths have been tested; and owners know what event requires revision. If any of these are missing, label the matrix provisionally approved for planning and close the gaps before dependent activity begins.
A practical sponsor may combine this with Vendor Governance for performance and escalation and Sponsor Oversight for independent oversight evidence.
Need a responsibility model ready for kickoff?
BioBoston CRO Responsibility Matrix support can help structure clinical trial roles, reconcile scope and approval pathways, and create a controlled decision-to-evidence map for sponsor and provider teams.
